Adma Biologics, INC 8-K filings
NASDAQ
8-K: ADMA Biologics Receives FDA Approval for Extended Room Temperature Storage of ASCENIV and BIVIGAM
ADMA Biologics has secured FDA approval to extend the room temperature storage conditions for its ASCENIV and BIVIGAM products, allowing for 4-week storage at any point during their 36-month shelf life.
NASDAQ
ADMA Biologics showcases its vertically integrated model, strong growth outlook, and differentiated position in the specialty biologics market in a new corporate presentation.
NASDAQ
ADMA Biologics has disclosed executive compensation for 2024, a CFO transition to a consulting role, and a consulting agreement with the outgoing CFO.
NASDAQ
ADMA Biologics announced its fourth quarter and full year 2023 financial results, achieving positive adjusted net income for the full year and increasing its revenue and earnings guidance for 2024 and 2025.
NASDAQ
ADMA Biologics has successfully implemented its new Artificial Intelligence program, ADMAlytics, to optimize production processes.